Study S001820

A Randomised Study to Investigate Steady State Semaglutide Exposure of a New Formulation of Oral Semaglutide in Healthy Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05784402
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 264
Start: 2023-03-16
Primary completion: 2024-02-23
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Participants
Interventions: DRUG:Semaglutide J; DRUG:Semaglutide C
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1279-6289

Registered primary outcomes

AUC0-24h,semaglutide,SS; area under the semaglutide plasma concentration-time curve during a dosing interval at steady state [From 0 to 24 hours after dosing on days 77, 112 and 147]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.